Common Sedative Emerges as Strongest Shield Against Postoperative Delirium in Older Surgery Patients

Postoperative delirium is one of the most feared complications of major surgery in older adults, a sudden and often devastating state of confusion that can leave a grandmother who walked into the hospital for a hip replacement unable to recognize her own family days later. Now, a sweeping synthesis of randomized clinical trial evidence suggests that a widely available sedative drug may offer the most reliable pharmacological protection against this condition. A systematic review and network meta-analysis published in BMC Geriatrics has compared multiple drug strategies tested to prevent postoperative delirium after major orthopedic surgery, and the results point to dexmedetomidine as the intervention backed by the largest and most precise body of evidence.

The research team, led by Xiaoyu Yang and Xiaoning Jiang with corresponding author Fan Wang, drew on trials conducted in patients aged 60 and older undergoing major orthopedic procedures such as hip and knee surgery. These operations are among the most common reasons older adults end up in the operating room, and they carry a substantial risk of delirium. The condition is not a minor side effect. Postoperative delirium is associated with longer hospital stays, increased rates of institutional discharge, accelerated cognitive decline, and higher mortality. For decades, clinicians have relied mainly on non-drug prevention strategies, such as reorientation protocols, sleep hygiene, early mobilization, and vision and hearing aids, because no pharmacological approach had been clearly validated.

The appeal of drug-based prevention lies in the biology of delirium itself. Scientists believe that surgical trauma triggers a cascade of neuroinflammatory events. Tissue injury releases damage-associated molecular patterns, which activate immune signaling and can drive elevations in inflammatory molecules such as interleukin-6 and tumor necrosis factor-alpha. These signals can disrupt the blood-brain barrier and disturb neurotransmitter systems, particularly acetylcholine and the N-methyl-D-aspartate receptor pathways, tipping the aging brain into the acute disorganization that defines delirium. The drugs tested in the trials reviewed here were chosen precisely because they interact with these pathways, either by damping inflammation or by protecting neurons from stress-related injury.

To compare these strategies fairly, the researchers performed a network meta-analysis, a statistical technique that allows both direct comparisons, from trials that tested two treatments against each other, and indirect comparisons, inferred through shared comparators such as placebo. They systematically searched four electronic databases for randomized controlled trials evaluating perioperative pharmacological strategies for postoperative delirium or postoperative cognitive outcomes in older orthopedic patients. Crucially, for the primary quantitative analysis, delirium had to be diagnosed using a validated instrument, such as the Confusion Assessment Method or the 3-Minute Diagnostic Confusion Assessment Method, rather than by informal clinical impression. This requirement matters because delirium is notoriously under-recognized at the bedside, and screening tools dramatically change detection rates.

Eighteen randomized controlled trials encompassing 4,132 participants made it into the systematic review. Of these, thirteen trials involving 3,466 participants formed the primary network for the delirium analysis, containing nine distinct treatment nodes. The team used a frequentist random-effects model and, importantly, modeled active drug comparisons separately from inert placebo or standard-care controls, a methodological choice designed to avoid distorting effect estimates. They reported odds ratios with 95 percent confidence intervals, which describe the precision of the observed effect, and also 95 percent prediction intervals, which estimate the range of effects one might expect in a future, real-world setting. They ranked treatments using P-scores, built a league table of all pairwise comparisons, mapped how much each trial contributed to the network, and graded the certainty of the evidence using a GRADE and CINeMA-style framework.

The headline findings were striking. Four interventions produced odds ratios whose confidence and prediction intervals both excluded the value of one, the threshold of no effect. An anti-inflammatory bundle showed the largest estimated benefit, with an odds ratio of 0.21, meaning roughly a 79 percent reduction in the odds of delirium compared with control. Dexmedetomidine produced an odds ratio of 0.37, dexamethasone 0.36, and parecoxib 0.46. Among these, dexmedetomidine stood out for a different reason: it was supported by the largest evidence base in the network, making its estimate the most trustworthy of the group. Dexmedetomidine is an alpha-2 adrenergic agonist, a sedative that calms patients without suppressing respiration, and it is already widely used in intensive care and anesthesia settings, which makes a preventive role particularly practical.

Not every candidate drug fared as well. Esketamine, an anesthetic agent acting on the NMDA receptor that had attracted interest for its neuroprotective potential, did not show a statistically significant protective effect against placebo, with an odds ratio of 0.77 and a confidence interval spanning 0.33 to 1.76. The researchers also tested whether the type of surgery modified how well the drugs worked, comparing effects across different orthopedic contexts. It did not. Interaction tests for dexmedetomidine, parecoxib, and propofol all returned non-significant p-values of 0.26, 0.50, and 0.53 respectively, meaning the analysis demonstrated no surgical-stress-dependent treatment hierarchy. In other words, there was no evidence that a particular operation type made one drug strategy clearly superior to another.

The authors were careful to temper enthusiasm with appropriate scientific caution. Certainty of the evidence remains moderate at best, and the network is sparse, with no independent closed loops, meaning the indirect estimates rest on relatively thin connections between trials. Several of the promising effect estimates, including the eye-catching figure for the anti-inflammatory bundle, rest on single small trials that could overstate true benefit. This is a well-known phenomenon in meta-analysis, where early small studies often report larger effects than later, better-powered replications. The prediction intervals, which account for between-study heterogeneity, help guard against false confidence, and the fact that four interventions passed that stricter test is genuinely encouraging, but the authors concluded that adequately powered, standardized head-to-head randomized trials are still needed before any drug can be recommended for routine prophylaxis.

Even so, the implications for perioperative medicine are significant. Hip fracture repair and joint replacement are performed millions of times each year worldwide, and the population undergoing them continues to age. If a low-cost, well-characterized drug such as dexmedetomidine, delivered during and around surgery, can meaningfully cut delirium risk, the potential public health impact is enormous, spanning shorter hospitalizations, fewer nursing home admissions, and preserved cognition for vulnerable patients. The study also delivers a methodological message to the field: future trials should use validated delirium screening instruments, consistent dosing protocols, and direct comparisons between the leading candidates rather than yet another placebo-controlled test of a single agent. Until those head-to-head studies arrive, this analysis provides the clearest map yet of which pharmacological strategies deserve the spotlight, and it places a familiar sedative at the center of one of geriatric surgery’s most urgent unanswered questions.

Subject of Research: Pharmacological prevention of postoperative delirium in older adults undergoing major orthopedic surgery

Article Title: Perioperative pharmacological prophylaxis of postoperative delirium after major orthopedic surgery in older adults: a systematic review and network meta-analysis of randomized controlled trials

Article References: Yang, X., Jiang, X., Xiao, R., Liu, J., Guo, Y., Ji, Y., Zhao, F., & Wang, F. (2026). Perioperative pharmacological prophylaxis of postoperative delirium after major orthopedic surgery in older adults: a systematic review and network meta-analysis of randomized controlled trials. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08430-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08430-6

Keywords: postoperative delirium, dexmedetomidine, orthopedic surgery, network meta-analysis, older adults, geriatrics, anesthesia, neuroinflammation, randomized controlled trials, dexamethasone, parecoxib, perioperative medicine